Biography for Tracy Staton
Tracy Staton, Senior Editor
Tracy Staton is the editor of FiercePharma and FiercePharmaMarketing. She has been a freelance writer for eight years, but before that served as editor of the Dallas Business Journal, editor of Texas Business magazine, and a senior editor at American Way, the inflight magazine of American Airlines. She is based in Vermont, and can be reached at firstname.lastname@example.org or find her on LinkedIn.
Articles by Tracy Staton
France's Servier is plotting big cuts in its home country as part of a companywide refocus. The privately held drugmaker plans to lay off 610 workers, mostly in its commercial operations within France, where sales have plummeted by almost half over the past 5 years.
The U.S. Treasury Department is rushing out a new set of guidelines on the "tax inversion" deals that have allowed drugmakers to save big money on taxes by buying overseas rivals and moving their domiciles to friendlier jurisdictions.
Pfizer and Allergan are coming down to the wire on a merger that would be the biggest pharma deal ever. The all-stock transaction would be worth up to $150 billion, at a price of $370 to $380 per share, according to media reports, though analysts have estimated a per-share price of up to $400.
Mallinckrodt's shares have suffered since short seller Citron Research called out the company's pricing policies and marketing efforts last week. A newly disclosed price hike set off a storm of criticism earlier this week. Now, the company is seeking to gin up shareholder support with a $500 million boost to its stock-buyback program.
Analysts handicapping the competitors in hepatitis C, current and future, say Gilead Sciences is likely to continue dominating the field, though it might cede some niches to newer rivals.
Express Scripts will put its money behind a new value-based reimbursement model next year, using comparative data and indication-specific pricing to favor "clinically superior" meds. The pharmacy benefits manager will roll out the approach in cancer first, with anti-inflammatory meds close behind.
Pfizer and Allergan are close to striking a deal that would be the biggest of 2015 by far--and the biggest healthcare deal ever, Bloomberg reports. The price: $370 to $380 per share, or almost $150 billion.
Men have pharma needs, too. Traditional pharma marketing strategies target women, following common marketing wisdom that women control or influence the vast majority of household purchases, up to 80% or more depending on which study you read. But new research from ID Media points to men taking a more active role in healthcare.
If Pfizer does make a friendly deal for Allergan, CEO Ian Read will be giving up his seat at the helm. That's the word from sources at Pfizer, who told Forbes' John LaMattina that current negotiations depend on Allergan CEO Brent Saunders taking charge at the combined company.
The FDA put Bristol-Myers Squibb's immuno-oncology drug Opdivo on its priority review fast track for a new use in kidney cancer. It would be yet another new indication for Opdivo, which was first approved for melanoma last year and now boasts two indications in lung cancer.